Introduction:
Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, forming a new company named Novonesis. The merger aims to lead in innovating solutions for a healthier living, better food, reduced chemical use, and climate-neutral practices. Novonesis is expected to show robust financial growth, with projected organic revenue growth of 6-8% through 2025 and an estimated annual revenue of € 3.7 bn. The company has outlined its financial reporting structure and will report in EUR. Novonesis aims to achieve carbon neutrality by 2050 and a balanced gender representation in senior management by 2030.
- Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, forming a new company named Novonesis.
- Novonesis aims to lead in innovating solutions for a healthier living, better food, reduced chemical use, and climate-neutral practices.
- Novonesis is expected to achieve robust financial growth, with projected organic revenue growth of 6-8% through 2025 and an estimated annual revenue of € 3.7 bn.
- The company has outlined its financial reporting structure and will report in EUR.
- Novonesis aims to achieve carbon neutrality by 2050 and a balanced gender representation in senior management by 2030.
Conclusion:
Novonesis, the newly formed company resulting from the merger between Novozymes A/S and Chr. Hansen Holding A/S, aims to lead in innovating biosolutions for various sectors such as healthcare, agriculture, and environmental sustainability. With a projected robust financial growth and a focus on achieving carbon neutrality and gender diversity in its management, Novonesis is poised to make significant contributions to a healthier and more sustainable future.
